Garuda - Garba Rujukan Digital

Neurological findings in patients with COVID-19: a systematic review Mawaddah Ar Rochmah; Sekar Satiti; Ismail Setyopranoto; Indra Sari Kusuma Harahap; Desin Pambudi Sejahtera; Dhite Bayu Nugroho; Sri Sutarni
Journal of the Medical Sciences (Berkala Ilmu Kedokteran) Vol 52, No 3 (2020): Special Issue: COVID-19
Publisher : Journal of the Medical Sciences (Berkala Ilmu Kedokteran)

Since the emerging of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in Wuhan, China at the end of 2019, the coronavirus disease 2019 (COVID-19) has become pandemic for months. Due to fast increased number of the positive patients with COVID-19, SARS-CoV-2 is considered highly pathogenic virus with various clinical presentations. Apart from the typical respiratory symptoms, neurological complains in COVID-19 involving central and peripheral nervous systems have been reported. This paper aimed to review the neurological findings reported in patients with COVID-19. We qualitatively reviewed studies reporting COVID-19 patient(s) with neurological manifestations according to the recommendations of PRISMA statement.There were twelve studies included in this brief review. We found that patients with neurological findings were reported ranging from symptomatic complain of headache and dizziness to specific neurological diseases/syndromes, such as meningitis/encephalitis, acute cerebrovascular diseases, Guillain-Barré syndrome, and Miller Fisher syndrome. This review suggests the possible neurological involvement in COVID-19. We hope to raise the awareness of the health workers in taking care of the patients with COVID-19 and neurological diseases.

Hubungan Hipertensi Terhadap Kematian Pasien Covid-19 Dengan Diabetes Melitus Tipe 2 di RSUP dr. Sardjito Fadhilah, Farah; Susanti, Vina Yanti; Nugroho, Dhite Bayu; Adhikara, Imam Manggalya; Handajani, Fitri
CoMPHI Journal: Community Medicine and Public Health of Indonesia Journal Vol. 4 No. 3 (2024): Februari
Publisher : Perhimpunan Dokter Kedokteran Komunitas dan Kesehatan Masyarakat Indonesia (PDK3MI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37148/comphijournal.v4i3.199

Diabetes mellitus and hypertension are co-morbidities that are often found in COVID-19 patients. Diabetes can reduce the body's immunity and increase the rate of viral replication, and is associated with vascular problems. Hypertension is one of the comorbid diabetes with high morbidity and mortality. To determine the relationship between hypertension and the death of COVID-19 patients with type 2 diabetes mellitus at Dr Sardjito General Hospital. Observational study with a retrospective cohort study design, using COVID-19 registry data at Dr Sardjito General Hospital for the period March 2020-July 2021. COVID-19 patients with type 2 diabetes mellitus who had hypertension and those who did not have hypertension were selected at Dr Sardjito General Hospital and Collected data on mortality, age, sex, other comorbidities, severity and length of stay. Data were processed using SPSS, in univariate, bivariate, and multivariate analysis models. the results of multivariate analysis using logistic regression found that hypertension, age, and ischemic heart disease did not have a significant association with the death of COVID-19 patients with type 2 diabetes mellitus. The variable that had the greatest power as a predictor of death in COVID-19 patients with diabetes mellitus type 2 is ARDS with a risk of death 20.8 times higher than without ARDS. Patients with kidney failure are at risk of dying 2.7 times higher than those without kidney failure. The addition of length of stay (LOS) 1 day of treatment reduces the risk of death by 16.3%. Hypertension has no significant relationship as a predictor of death in COVID-19 patients with type 2 diabetes mellitus at Dr Sardjito General Hospital. Significant predictors of death in this study were ARDS, kidney failure, and were associated with length of stay (LOS).

Efektivitas Citicoline dalam Terapi Demensia Mawaddah Ar Rochmah; Erupsiana Fitri Indrihapsari; Dhite Bayu Nugroho
Cermin Dunia Kedokteran Vol 51 No 1 (2024): Kedokteran Umum
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v51i1.990

Background: In the development of pharmacological therapy for dementia, especially Alzheimer's disease, several types of therapy are widely used: acethylcholine esterase inhibitors/AChEI, N-methyl-D-aspartate (NMDA) receptors inhibitors, and cholinergic precursor. Aim: To review the evidence on the effectiveness of citicoline supplementation to the standard therapy of dementia to prevent the progression or improve the manifestations of dementia. Methods: A literature search was performed in three following databases: Pubmed, EBSCOhost, Scopus, and Cochrane within the last ten years. Results: Of the 239 articles, five studies were eligible for critical appraisal. Four studies showed a significant mean MMSE score increase in the citicoline + standard therapy group (intervention) compared to the standard therapy group (control) during the follow up period between 3 – 12 months. One study showed a significant mean MMSE score increase of in the intervention group compared to the control group. Conclusion: Oral citicoline supplementation of 1,000 mg/day to the standard therapy showed a positive effect on cognitive function in dementia patients. Critical appraisal of validity and application of the included studies should be considered upon daily clinical application.

Efektivitas Citicoline dalam Terapi Demensia Ar Rochmah, Mawaddah; Indrihapsari, Erupsiana Fitri; Nugroho, Dhite Bayu
Cermin Dunia Kedokteran Vol 51 No 1 (2024): Kedokteran Umum
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v51i1.990

Background: In the development of pharmacological therapy for dementia, especially Alzheimer's disease, several types of therapy are widely used: acethylcholine esterase inhibitors/AChEI, N-methyl-D-aspartate (NMDA) receptors inhibitors, and cholinergic precursor. Aim: To review the evidence on the effectiveness of citicoline supplementation to the standard therapy of dementia to prevent the progression or improve the manifestations of dementia. Methods: A literature search was performed in three following databases: Pubmed, EBSCOhost, Scopus, and Cochrane within the last ten years. Results: Of the 239 articles, five studies were eligible for critical appraisal. Four studies showed a significant mean MMSE score increase in the citicoline + standard therapy group (intervention) compared to the standard therapy group (control) during the follow up period between 3 – 12 months. One study showed a significant mean MMSE score increase of in the intervention group compared to the control group. Conclusion: Oral citicoline supplementation of 1,000 mg/day to the standard therapy showed a positive effect on cognitive function in dementia patients. Critical appraisal of validity and application of the included studies should be considered upon daily clinical application.

Title

Found 4 Documents
Search

Abstract

Abstract

Abstract

Abstract

Title Search

Found 4 Documents Search

Abstract

Abstract

Abstract

Abstract

Title

Found 4 Documents
Search